Barriers to HCV treatment in the era of triple therapy: a prospective multi‐centred study in clinical practice

Abstract

Despite the high efficacy of triple therapy, only a small proportion of patients receive the treatment. The causes related to non-treatment depend on patient factors, disease stage and characteristics of the health-service provision.

Efficacy of motivational enhancement therapy on alcohol use disorders in patients with chronic hepatitis C: a randomized controlled trial

“…Prior data indicate that patients with significant alcohol problems can initiate and benefit successfully from antiviral therapy, but typically require multi‐disciplinary support . Our data are consistent with prior research indicating that initiation of antiviral therapy is influenced by patient, provider and system factors . Future studies should determine whether efforts to reduce alcohol use increase initiation of antiviral therapy and outcomes such as a sustained virological response.…”

Value and innovation of direct-acting antivirals: long-term health outcomes of the strategic plan for the management of hepatitis C in Spain

“…For both strategies, the average cost of treatment monitoring was €1,257 for the post-DAA strategy and €2,371 for the pre-DAA strategy. These costs included different treatment durations (8,12,24, or 48 weeks) and were calculated from published data (33). The annual health costs associated with each health state were obtained from published data (30,33).…”

“…The efficacy of oral antiviral therapies based on pegylated IFNα (peg-IFN) that have been developed during the last decade has had a relatively low impact on the burden of HCV infection (8). Modelling studies conducted using data from a Spanish population evaluated outcomes following the use of peg-IFN and ribavirin (peg-IFN/RBV) or triple therapy with an HCV protease inhibitor (boceprevir or telaprevir) and peg-IFN/RBV.…”

The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service

“…The highest prevalence of hepatitis C virus (HCV) infection is in people who inject drugs (PWID) or who have a history of injecting drug use, and treatment uptake is particularly low in this group [ 4 , 5 ]. The reasons for poor treatment uptake are multifactorial and include long and often toxic treatment regimens, difficulties in accessing care provided from tertiary hospitals by specialists, stigma from health service providers and historically, policies of excluding current PWID from treatment [ 6 – 8 ].…”